Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178696 · ClinicalTrials.gov registry record · Phase 4
Predictors of Antidepressant Response
A Phase 4 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT02178696 is a Phase 4 study that has completed, run by University of Michigan. The registered enrollment target is 44 participants.
The verdict
NCT02178696, a Phase 4 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
Major depression is a highly prevalent, frequently debilitating illness that too often fails to respond to currently available treatments such as antidepressant medication. Furthermore, randomized controlled trials of antidepressants consistently demonstrate large placebo effects. The investigators hypothesize that individual differences in the function of key brain circuits underlie the observed variability in clinical responses to both placebo and antidepressant medication. This study will test this hypothesis by recruiting treatment-seeking volunteers with major depression, with or without comorbid nicotine dependence. Volunteers will participate in positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scans in the context of a treatment trial in which they will receive both placebo and antidepressant medication. A major goal of the study is to improve prediction of individual clinical responses in future treatment trials in which brain imaging may be unavailable, and to study the mechanisms of antidepressant response in Major Depression.
Interventions
- OTHER Placebo, identified as placebo to participants
- DRUG Celexa or other antidepressant as clinically indicated
- OTHER Placebo, identifed to participants as "Active medication"
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178696
The ClinicalTrials.gov registry entry for NCT02178696 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo, identified as placebo to participants is the first listed.
NCT02178696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02178696 about?
NCT02178696 is a clinical study titled "Predictors of Antidepressant Response". Major depression is a highly prevalent, frequently debilitating illness that too often fails to respond to currently available treatments such as antidepressant medication. Furthermore, randomized controlled trials of antidepressants consistently demonstrate large placebo effects. The investigators ...
What is the current status of trial NCT02178696?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2011-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02178696?
The interventions under investigation include: Placebo, identified as placebo to participants (OTHER), Celexa or other antidepressant as clinically indicated (DRUG), Placebo, identifed to participants as "Active medication" (OTHER).
Who is sponsoring clinical trial NCT02178696?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.